Sialyl Lewis A - a key glycobiological probe to unlock cell recognition and disease intervention

Sialyl Lewis A is one of the important core structures of glycoconjugates on the cell surface and is known as the "identification code" between cells. It is not only a key mediator of cell adhesion and signaling, but also a highly anticipated star molecule in modern biomedicine, especially in the fields of cancer diagnosis, inflammation targeted therapy and immune regulation.

Chemical Information

Chemical name: Sialyl Lewis A tetrasaccharide, sodium salt

Common name: Sialyl Lewis A

English name: Sialyl Lewis A, Sodium Salt

Chemical formula: C31H52N2O23

Molecular weight: 820.74 g/mol

CAS number: 92448-22-1

Structural features

Sialyl Lewis A is a complex tetrasaccharide structure. Its unique features are:

Precise terminal structure: sialic acid (N-acetylneuraminic acid) and fucose are jointly modified on the core skeleton of lactosamine, forming a unique spatial conformation.

High-affinity ligand for E-selectin: This precise structure enables it to be specifically recognized and bound by E-selectin (E-Selectin) on vascular endothelial cells, which is a key "anchoring" step in the process of inflammation and tumor cell metastasis.

Important biomarker: This structure is the core epitope of the clinically widely used tumor marker CA19-9.

Main applications and advantages

1. Core targets in cancer research and diagnosis

Tumor metastasis monitoring: The expression of sialic acid Lewis A is significantly up-regulated in various adenocarcinomas (such as pancreatic cancer, colorectal cancer, gastric cancer). It mediates the adhesion of circulating tumor cells to vascular endothelium and is a key initial step in hematogenous tumor metastasis. Sialyl Lewis A is an ideal tool for studying the mechanism of cancer cell metastasis and developing anti-metastasis drugs.

Diagnostic reagent development: As the core antigen of the CA19-9 detection kit, high-purity sialic acid Lewis A is crucial to ensuring the accuracy, sensitivity and specificity of diagnostic reagents, and is an indispensable raw material in the field of in vitro diagnostics (IVD).

2. Innovative platform for anti-inflammatory drug development

Blocking the inflammatory cascade: At sites of acute or chronic inflammation, leukocytes bind to activated endothelial cell E-selectin through Sialyl Lewis A on their surface, triggering leukocyte rolling and exudation. The use of Sialyl Lewis A or its mimics can competitively antagonize this interaction, providing a clear target for the development of new anti-inflammatory drugs for the treatment of autoimmune diseases, ischemia-reperfusion injury, etc.

3. Immunomodulation and drug delivery

Targeted delivery system: Taking advantage of the high expression of E-selectin in specific diseased areas (such as tumor neovascularization and inflammatory areas), the Sialyl Lewis A structure can be integrated into the surface of liposomes or nanoparticles to construct an intelligent targeted drug delivery system to achieve precise drug delivery, improve efficacy and reduce side effects.

Research on immune cell function: Studying the interaction between Sialyl Lewis A and selectins will help to deeply understand the homing, migration and activation mechanisms of immune cells and provide new insights into immunotherapy.

Conclusion

Sialyl Lewis A is not just a sugar chain molecule, it is a bridge connecting cell recognition, disease occurrence and precision medicine. From the early diagnosis of highly lethal cancers to the development of innovative anti-inflammatory drugs to cutting-edge targeted delivery technologies, its value is being continuously explored.